Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2016

Open Access 01-12-2016 | Research

Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?

Authors: Gerdie M. de Jong, Jasper J. Slager, Annelies Verbon, Jaap J. van Hellemond, Perry J. J. van Genderen

Published in: Malaria Journal | Issue 1/2016

Login to get access

Abstract

Background

Levels of both angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) correlate with malaria disease severity and are proposed as biomarkers and possible therapeutic targets. To establish their role in malaria, a systematic review was performed of the literature on Ang-1 and Ang-2 with regard to their potential as biomarkers in malaria and discuss their possible place in adjuvant treatment regimens.

Methods

Ten electronic databases were systematically searched to identify studies investigating Ang-1 and Ang-2 in human and murine malaria in both clinical and experimental settings. Information about the predictive value of Ang-1 and Ang-2 for disease severity and their regulatory changes in interventional studies were extracted.

Results

Some 579 studies were screened; 26 were included for analysis. In all five studies that determined Ang-1 levels and in all 11 studies that determined Ang-2 in different disease severity states in falciparum malaria, a decline in Ang-1 and an increase of Ang-2 levels was associated with increasing disease severity. All nine studies that determined angiopoietin levels in Plasmodium falciparum patients to study their ability as biomarkers could distinguish between multiple disease severity states; the more the disease severity states differed, the better they could be distinguished. Five studies differentiating malaria survivors from non-survivors with Ang-2 as marker found an AUROC in a range of 0.71–0.83, which performed as well or better than lactate. Prophylactic administration of FTY720, rosiglitazone or inhalation of nitric oxide (NO) during malaria disease in mice resulted in an increase in Ang-1, a decrease in Ang-2 and an increased survival. For rosiglitazone, a decrease in Ang-2/Ang-1 ratio was observed after post-infection treatment in mice and humans with malaria, but for inhalation of NO, an effect on Ang-1 and survival was only observed in mice.

Conclusion

Both Ang-1 and Ang-2 levels correlate with and can distinguish between malaria disease severity states within the group of malaria-infected patients. However, distinct comparisons of disease severity states were made in distinct studies and not all distinctions made had clinical relevance. Changes in levels of Ang-1 and Ang-2 might also reflect treatment effectiveness and are promising therapeutic targets as part of multi-targeted therapy.
Appendix
Available only for authorised users
Literature
1.
WHO. World malaria report. Geneva: World Health Organization; 2015.
2.
Udomsangpetch R, Wahlin B, Carlson J, Berzins K, Torii M, Aikawa M, et al. Plasmodium falciparum-infected erythrocytes form spontaneous erythrocyte rosettes. J Exp Med. 1989;169:1835–40.CrossRefPubMed
3.
Carvalho BO, Lopes SCP, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, et al. On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J Infect Dis. 2010;202:638–47.CrossRefPubMed
4.
Hemmer CJ, Holst FGE, Kern P, Chiwakata CB, Dietrich M, Reisinger EC. Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop Med Int Health. 2006;11:817–23.CrossRefPubMed
5.
Hviid L, Theander TG, Elhassan IM, Jensen JB. Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett. 1993;36:51–8.CrossRefPubMed
6.
Bae JS, Rezaie AR. Thrombin upregulates the angiopoietin-Tie2 axis: endothelial protein C receptor occupancy prevents the thrombin mobilization of angiopoietin 2 and P-selectin from Weibel–Palade bodies. J Thromb Haemost. 2010;8:1107–15.PubMedPubMedCentral
7.
Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL. Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation. 1997;96:605–13.PubMed
8.
Watanabe K, Tanaka K. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells. Atherosclerosis. 1983;48:57–70.CrossRefPubMed
9.
Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053–60.PubMed
10.
Dole VS, Bergmeier W, Mitchell HA, Eichenberger SC, Wagner DD. Activated platelets induce Weibel–Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood. 2005;106:2334–9.CrossRefPubMedPubMedCentral
11.
De Mast Q, Groot E, Lenting PJ, De Groot PG, McCall M, Sauerwein RW, et al. Thrombocytopenia and release of activated von Willebrand factor during early Plasmodium falciparum malaria. J Infect Dis. 2007;196:622–8.CrossRefPubMed
12.
Mankhambo LA, Banda DL, Jeffers G, White SA, Balmer P, Nkhoma S, et al. The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Crit Care. 2010;14:R91.CrossRefPubMedPubMedCentral
13.
Phanthanawiboon S, Limkittikul K, Sakai Y, Takakura N, Saijo M, Kurosu T. Acute systemic infection with dengue virus leads to vascular leakage and death through tumor necrosis factor-α and Tie2/Angiopoietin signaling in mice lacking type i and ii interferon receptors. PLoS ONE. 2016;11:e0148564.CrossRefPubMedPubMedCentral
14.
Michels M, Van Der Ven AJAM, Djamiatun K, Fijnheer R, De Groot PG, Griffioen AW, et al. Imbalance of angiopoietin-1 and-2 in severe dengue; relationship with thrombocytopenia, endothelial activation, and vascular stability. Angiogenesis. 2011;14:105.
15.
Page AV, ConradLiles W. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence. 2013;4:507–16.CrossRefPubMed
16.
17.
Darwish I, Conrad Liles W. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction. Virulence. 2013;4:572–82.CrossRefPubMed
18.
Silver KL, Kain KC, Liles WC. Endothelial activation and dysregulation: a common pathway to organ injury in infectious diseases associated with systemic inflammation. Drug Discovery Today Dis Mech. 2007;4:215–22.CrossRef
19.
David S, Kümpers P, Van Slyke P, Parikh SM. Mending leaky blood vessels: the angiopoietin-Tie2 pathway in sepsis. J Pharmacol Exp Ther. 2013;345:2–6.CrossRefPubMed
20.
Díez-Padrisa N, Bassat Q, Roca A. Serum biomarkers for the diagnosis of malaria, bacterial and viral infections in children living in malaria-endemic areas. Drugs Today (Barc). 2011;47:63–75.CrossRefPubMed
21.
Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel–Palade bodies. Blood. 2004;103:4150–6.CrossRefPubMed
22.
Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29:2011–22.CrossRefPubMedPubMedCentral
23.
24.
Van Der Heijden M, Van Nieuw Amerongen GP, Chedamni S, Van Hinsbergh VWM, Groeneveld ABJ. The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opin Ther Targets. 2009;13:39–53.CrossRefPubMed
25.
Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS ONE. 2009;4:e4912.CrossRefPubMedPubMedCentral
26.
Serghides L, McDonald CR, Lu Z, Friedel M, Cui C, Ho KT, et al. PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog. 2014;10:e1003980.CrossRefPubMedPubMedCentral
27.
Conroy AL, Glover SJ, Hawkes M, Erdman LK, Seydel KB, Taylor TE, et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study. Crit Care Med. 2012;40:952–9.CrossRefPubMedPubMedCentral
28.
Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, et al. Whole blood angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J. 2009;8:295.CrossRefPubMedPubMedCentral
29.
Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, et al. Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS ONE. 2010;5:e15291.CrossRefPubMedPubMedCentral
30.
Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, et al. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS ONE. 2011;6:e17440.CrossRefPubMedPubMedCentral
31.
Gomes LT, Alves-Junior ER, Rodrigues-Jesus C, Nery AF, Gasquez-Martin TO. Erratum: angiopoietin-2 and angiopoietin-2/angiopoietin-1 ratio as indicators of potential severity of Plasmodium vivax malaria in patients with thrombocytopenia. PLoS ONE. 2015;10:e0117651.CrossRef
32.
Jain V, Lucchi NW, Wilson NO, Blackstock AJ, Nagpal AC, Joel PK, et al. Plasma levels of angiopoietin-1 and -2 predict cerebral malaria outcome in Central India. Malar J. 2011;10:383.CrossRefPubMedPubMedCentral
33.
Prapansilp P, Medana I, Mai NTH, Day NPJ, Phu NH, Yeo TW, et al. A clinicopathological correlation of the expression of the angiopoietin-Tie-2 receptor pathway in the brain of adults with Plasmodium falciparum malaria. Malar J. 2013;12:50.CrossRefPubMedPubMedCentral
34.
Yeo TW, Lampah DA, Gitawat R, Tjitra E, Kenangalem E, Piera K, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA. 2008;105:17097–102.CrossRefPubMedPubMedCentral
35.
Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog. 2010;6:e1000868.CrossRefPubMedPubMedCentral
36.
Brouwers J, Noviyanti R, Fijnheer R, de Groot PG, Trianty L, Mudaliana S, et al. Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers. PLoS ONE. 2013;8:e64850.CrossRefPubMedPubMedCentral
37.
Moxon CA, Chisala NV, Wassmer SC, Taylor TE, Seydel KB, Molyneux ME, et al. Persistent endothelial activation and inflammation after Plasmodium falciparum infection in Malawian children. J Infect Dis. 2014;209:610–5.CrossRefPubMed
38.
Finney CAM, Hawkes CA, Kain DC, Dhabangi A, Musoke C, Cserti-Gazdewich C, et al. S1P is associated with protection in human and experimental cerebral malaria. Mol Med. 2011;17:717–25.CrossRefPubMedPubMedCentral
39.
Kim H, Erdman LK, Lu Z, Serghides L, Zhong K, Dhabangi A, et al. Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria. Infect Immun. 2014;82:371–9.CrossRefPubMedPubMedCentral
40.
Serghides L, Kim H, Lu Z, Kain DC, Miller C, Francis RC, et al. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS ONE. 2011;6:e27714.CrossRefPubMedPubMedCentral
41.
Hawkes MT, Conroy AL, Opoka RO, Hermann L, Thorpe KE, McDonald C, et al. Inhaled nitric oxide as adjunctive therapy for severe malaria: a randomized controlled trial. Malar J. 2015;14:421.CrossRefPubMedPubMedCentral
42.
Mwanga-Amumpaire J, Carroll RW, Baudin E, Kemigisha E, Nampijja D, Mworozi K, et al. Inhaled nitric oxide as an adjunctive treatment for cerebral malaria in children: a phase ii randomized open-label clinical trial. Open forum Infect Dis. 2015;2:ofv111.CrossRefPubMedPubMedCentral
43.
Barber BE, William T, Grigg MJ, Parameswaran U, Piera KA, Price RN, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog. 2015;11:e1004558.CrossRefPubMedPubMedCentral
44.
Rubach MP, Mukemba J, Florence S, Lopansri BK, Hyland K, Volkheimer AD, et al. Impaired systemic tetrahydrobiopterin bioavailability and increased oxidized biopterins in pediatric falciparum malaria: association with disease severity. PLoS Pathog. 2015;11:e1004655.CrossRefPubMedPubMedCentral
45.
Weinberg JB, Yeo TW, Mukemba JP, Florence SM, Volkheimer AD, Wang H, et al. Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria. J Infect Dis. 2014;210:913–22.CrossRefPubMedPubMedCentral
46.
Hanson J, Lee SJ, Hossain M, Anstey NM, Charunwatthana P, Maude RJ, et al. Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Med. 2015;13:122.CrossRefPubMedPubMedCentral
47.
Yeo TW, Lampah DA, Tjitra E, Piera K, Gitawati R, Kenangalem E, et al. Greater endothelial activation, Weibel–Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia. J Infect Dis. 2010;202:109–12.CrossRefPubMedPubMedCentral
48.
MacMullin G, MacKenzie R, Lau R, Khang J, Zhang H, Rajwans N, et al. Host immune response in returning travellers infected with malaria. Malar J. 2012;11:148.CrossRefPubMedPubMedCentral
49.
Abdi AI, Fegan G, Muthui M, Kiragu E, Musyoki JN, Opiyo M, et al. Plasmodium falciparum antigenic variation: relationships between widespread endothelial activation, parasite PfEMP1 expression and severe malaria. BMC Infect Dis. 2014;14:170.CrossRefPubMedPubMedCentral
50.
Graham SM, Chen J, Chung DW, Barker KR, Conroy AL, Hawkes MT, et al. Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial. Malar J. 2016;15:56.CrossRefPubMedPubMedCentral
51.
Stauga S, Hahn A, Brattig NW, Fischer-Herr J, Baldus S, Burchard GD, et al. Clinical relevance of different biomarkers in imported Plasmodium falciparum malaria in adults: a case control study. Malar J. 2013;12:246.CrossRefPubMedPubMedCentral
52.
Manning L, Davis TME. The mechanistic, diagnostic and prognostic utility of biomarkers in severe malaria. Biomark Med. 2013;7:363–80.CrossRefPubMed
53.
Kim H, Higgins S, Liles WC, Kain KC. Endothelial activation and dysregulation in malaria: a potential target for novel therapeutics. Curr Opin Hematol. 2011;18:177–85.CrossRefPubMed
54.
Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, Van Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279:52487–92.CrossRefPubMed
55.
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355–60.CrossRefPubMed
56.
Butler J, Lana D, Round O, LaMontagne K. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat. 2004;73:29–45.CrossRefPubMed
57.
Serghides L, Patel SN, Ayi K, Lu Z, Gowda DC, Liles WC, et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis. 2009;199:1536–45.CrossRefPubMedPubMedCentral
58.
Ballesteros I, Cuartero MI, Pradillo JM, de la Parra J, Pérez-Ruiz A, Corbí Á, et al. Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways. J Leukoc Biol. 2014;95:587–98.CrossRefPubMed
59.
Bhatia R, Matsushita K, Yamakuchi M, Morrell CN, Cao W, Lowenstein CJ. Ceramide triggers Weibel–Palade body exocytosis. Circ Res. 2004;95:319–24.CrossRefPubMed
60.
Day NPJ, Phu NH, Mai NTH, Chau TTH, Loc PP, Chuong LV, et al. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med. 2000;28:1833–40.CrossRefPubMed
61.
Van Genderen PJJ, Van Der Meer IM, Consten J, Petit PLC, Van Gool T, Overbosch D. Evaluation of plasma lactate as a parameter for disease severity on admission in travelers with Plasmodium falciparum malaria. J Travel Med. 2005;12:261–4.CrossRefPubMed
62.
Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, et al. The epidemiology of subclinical malaria infections in South–East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J. 2015;14:381.CrossRefPubMedPubMedCentral
63.
Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, et al. Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J Infect Dis. 2004;189:2220–6.CrossRefPubMed
64.
Beare NAV, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg. 2006;75:790–7.PubMedPubMedCentral
65.
Kuhne T, Hornstein A, Semple J, Chang W, Blanchette V, Freedman J. Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. Am J Hematol. 1995;50:40–5.CrossRefPubMed
66.
Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J, et al. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem. 2005;51:2365–8.CrossRefPubMed
67.
Riedl J, Mordmüller B, Koder S, Pabinger I, Kremsner PG, Hoffman SL, et al. Alterations of blood coagulation in controlled human malaria infection. Malar J. 2016;15:15.CrossRefPubMedPubMedCentral
68.
Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, et al. Platelet activation markers in patients with peripheral arterial disease. A prospective comparison of different platelet function tests. Thromb Haemost. 1997;78:1434–7.PubMed
69.
Prudhomme JG, Sherman IW, Land KM, Moses AV, Stenglein S, Nelson JA. Studies of plasmodium falciparum cytoadherence using immortalized human brain capillary endothelial cells. Int J Parasitol. 1996;26:647–55.CrossRefPubMed
70.
Bauer PR, Van Der Heyde HC, Sun G, Specian RD, Granger DN. Regulation of endothelial cell adhesion molecule expression in an experimental model of cerebral malaria. Microcirculation. 2002;9:463–70.CrossRefPubMed
71.
72.
Van Den Bruel A, Jones C, Thompson M, Mant D. C-reactive protein point-of-care testing in acutely ill children: a mixed methods study in primary care. Arch Dis Child. 2016;101:382–6.CrossRefPubMed
73.
Kok J, Ng J, Li SC, Giannoutsos J, Nayyar V, Iredell JR, et al. Evaluation of point-of-care testing in critically unwell patients: comparison with clinical laboratory analysers and applicability to patients with Ebolavirus infection. Pathology. 2015;47:405–9.CrossRefPubMed
74.
Mohanty S, Patel DK, Pati SS, Mishra SK. Adjuvant therapy in cerebral malaria. Indian J Med Res. 2006;124:245–60.PubMed
75.
John CC, Kutamba E, Mugarura K, Opoka RO. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti-Infect Ther. 2010;8:997–1008.CrossRefPubMedPubMedCentral
76.
Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Büscher P, Que I, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA. 2005;102:11468–73.CrossRefPubMedPubMedCentral
77.
Metadata
Title
Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?
Authors
Gerdie M. de Jong
Jasper J. Slager
Annelies Verbon
Jaap J. van Hellemond
Perry J. J. van Genderen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2016
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-016-1624-8

Other articles of this Issue 1/2016

Malaria Journal 1/2016 Go to the issue

Research

Contribution of the private sector healthcare service providers to malaria diagnosis in a prevention of re-introduction setting

Reviewer Acknowledgement

Reviewer acknowledgement 2015

Research

Monitoring iCCM referral systems: Bugoye Integrated Community Case Management Initiative (BIMI) in Uganda

Research

Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination?

Research

The role of gender on malaria preventive behaviour among rural households in Kenya

Research

Impact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zone
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits